Longeveron Issues Letter To Stockholders; Initiated $30M Rights Offering August 14; Phase 2 ELPIS II Trial In HLHS Surpasses 50% Enrollment
Portfolio Pulse from Benzinga Newsdesk
Longeveron's CEO has issued a letter to stockholders, highlighting the progress of their lead investigational product, Lomecel-B™, in multiple disease states. The company has initiated a $30 million Rights Offering and the Phase 2 ELPIS II trial in Hypoplastic Left Heart Syndrome (HLHS) has surpassed 50% enrollment. The company also announced the appointment of new members to its Board and executive leadership team.
September 11, 2023 | 1:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Longeveron's ongoing trials are progressing and nearing important clinical milestones. The company has also strengthened its leadership team and initiated a $30 million Rights Offering.
The progress in the trials of Longeveron's lead product, Lomecel-B™, and the strengthening of its leadership team indicate a positive outlook for the company. The initiation of a $30 million Rights Offering also suggests the company's confidence in its future prospects, which could positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100